Targeting CD155 by rediocide-A overcomes tumour immuno-resistance to natural killer cells

References

• Alter G, Malenfant JM, Altfeld M. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 294(1–2):15–22.
   PubMed Web of Science ®Google Scholar
• Bi J, Zheng X, Chen Y, Wei H, Sun R, Tian Z. 2014. TIGIT safeguards liver regeneration through regulating natural killer cell-hepatocyte crosstalk. Hepatology. 60(4):1389–1398.
   PubMed Web of Science ®Google Scholar
• Bowers JR, Readler JM, Sharma P, Excoffon KJDA. 2017. Poliovirus receptor: more than a simple viral receptor. Virus Res. 242:1–6.
   PubMed Web of Science ®Google Scholar
• Bronte V. 2018. The expanding constellation of immune checkpoints: a DNAMic control by CD155. J Clin Invest. 128(6):2199–2201.
   PubMed Web of Science ®Google Scholar
• Carlsten M, Baumann BC, Simonsson M, Jadersten M, Forsblom AM, Hammarstedt C, Bryceson YT, Ljunggren HG, Hellstrom-Lindberg E, Malmberg KJ. 2010. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome. Leukemia. 24(9):1607–1616.
   PubMed Web of Science ®Google Scholar
• Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M. 1997. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 79(12):2320–2328.
   PubMed Web of Science ®Google Scholar
• Cui L, Li J, Xie X. 2012. Rediocide A, an insecticide, induces G-protein-coupled receptor desensitization via activation of conventional protein kinase C. J Nat Prod. 75(6):1058–1062.
   PubMed Web of Science ®Google Scholar
• Erskine CL, Henle AM, Knutson KL. 2012. Determining optimal cytotoxic activity of human Her2neu specific CD8 T cells by comparing the Cr51 release assay to the xCELLigence system. J Vis Exp. 66:e3683.
   Google Scholar
• Gao J, Zheng Q, Xin N, Wang W, Zhao C. 2017. CD155, an oncoimmunologic molecule in human tumors. Cancer Sci. 108(10):1934–1938.
   PubMed Web of Science ®Google Scholar
• Gong C, Ni Z, Yao C, Zhu X, Ni L, Wang L, Zhu S. 2015. A high-throughput assay for screening of natural products that enhanced tumoricidal activity of NK Cells. Biol Proced Online. 17:12.
   PubMed Web of Science ®Google Scholar
• Jayasuriya H, Zink DL, Borris RP, Nanakorn W, Beck HT, Balick MJ, Goetz MA, Gregory L, Shoop WL, Singh SB. 2004. Rediocides B–E, potent insecticides from Trigonostemon reidioides. J Nat Prod. 67(2):228–231.
   PubMed Web of Science ®Google Scholar
• Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, Xia J, Tan TG, Sefik E, Yajnik V, et al. 2014. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 40(4):569–581.
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. 1998. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA. 95(13):7556–7561.
   PubMed Web of Science ®Google Scholar
• Kono T, Imai Y, Yasuda S-i, Ohmori K, Fukui H, Ichikawa K, Tomita S, Imura J, Kuroda Y, Ueda Y, et al. 2008. The CD155/poliovirus receptor enhances the proliferation of ras-mutated cells. Int J Cancer. 122(2):317–324.
   PubMed Web of Science ®Google Scholar
• Krasnova Y, Putz EM, Smyth MJ, Souza-Fonseca-Guimaraes F. 2017. Bench to bedside: NK cells and control of metastasis. Clin Immunol. 177:50–59.
   PubMed Web of Science ®Google Scholar
• Kucan Brlic P, Lenac Rovis T, Cinamon G, Tsukerman P, Mandelboim O, Jonjic S. 2019. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol. 16(1):40–52.
   PubMed Web of Science ®Google Scholar
• Li XY, Das I, Lepletier A, Addala V, Bald T, Stannard K, Barkauskas D, Liu J, Aguilera AR, Takeda K, et al. 2018. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J Clin Invest. 128(6):2613–2625.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang S, Xin J, Wang J, Yao C, Zhang Z. 2019. Role of NKG2D and its ligands in cancer immunotherapy. Am J Cancer Res. 9(10):2064–2078.
   PubMed Web of Science ®Google Scholar
• Martinet L, Smyth MJ. 2015. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol. 15(4):243–254.
   PubMed Web of Science ®Google Scholar
• Morvan MG, Lanier LL. 2016. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 16(1):7–19.
   PubMed Web of Science ®Google Scholar
• Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I, Akahori T, Kinoshita S, Nagai M, Konishi N, Nakajima Y. 2015. Clinical significance of CD155 expression in human pancreatic cancer. Anticancer Res. 35(4):2287–2297.
   PubMed Web of Science ®Google Scholar
• Raulet DH, Guerra N. 2009. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol. 9(8):568–580.
   PubMed Web of Science ®Google Scholar
• Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM, Arcos MJ, Banas H, Casas-Aviles I, Duran S, et al. 2019. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: novel immune checkpoints for natural killer cell-based cancer immunotherapy. Cancers. 11(6):877.
   PubMed Web of Science ®Google Scholar
• Utsintong M, Kaewnoi A, Leelamanit W, Olson AJ, Vajragupta O. 2009. Rediocides A and G as potential antitoxins against cobra venom. Chem Biodivers. 6(9):1404–1414.
   PubMed Web of Science ®Google Scholar
• Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L. 2014. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol. 44(6):1582–1592.
   PubMed Web of Science ®Google Scholar
• Voskoboinik I, Smyth MJ, Trapani JA. 2006. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol. 6(12):940–952.
   PubMed Web of Science ®Google Scholar
• Wendel M, Galani IE, Suri-Payer E, Cerwenka A. 2008. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 68(20):8437–8445.
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhu X, Su L, Zou C, Chen X, Hou Y, Gong C, Ng W, Ni Z, Wang L, et al. 2020. A high-throughput assay for screening natural products that boost NK cell-mediated killing of cancer cells. Pharm Biol. 58(1):357–366.
   PubMed Web of Science ®Google Scholar
• Yao C, Ni Z, Gong C, Zhu X, Wang L, Xu Z, Zhou C, Li S, Zhou W, Zhou C, et al. 2018. Rocaglamide enhances NK cell-mediated killing of non-small cell lung cancer cells by inhibiting autophagy. Autophagy. 14(10):1831–1844.
   PubMed Web of Science ®Google Scholar
• Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al. 2009. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 10(1):48–57.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H, et al. 2018. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 19(7):723–732.
   PubMed Web of Science ®Google Scholar
• Zhu S, Waguespack M, Barker SA, Li S. 2007. Doxorubicin directs the accumulation of interleukin-12 induced IFN gamma into tumors for enhancing STAT1 dependent antitumor effect. Clin Cancer Res. 13(14):4252–4260.
   PubMed Web of Science ®Google Scholar